IN8bio Inc

IN8bio Inc(INAB)の財務

$1.090

-0.010 (-0.91%)終値時点

INAB の収益性とマージン

Evaluating the bottom line, IN8bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -174.66%, provide a clear picture of how effectively INAB converts its operational activities into shareholder value.

INAB の同業比較

In the context of the broader market, INAB competes directly with industry leaders such as TSBX and SNSE. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, INAB's gross margin of N/A stands against TSBX's N/A and SNSE's N/A. Such benchmarking helps identify whether IN8bio Inc is trading at a premium or discount relative to its financial performance.

Financials

FY2025Q1
YoY:
-34.53%
-5.66M
Operating Profit
FY2025Q1
YoY:
-35.18%
-5.55M
Net Income after Tax
FY2025Q1
YoY:
-65.00%
-0.07
EPS - Diluted
FY2025Q1
YoY:
-60.93%
-3.12M
Free Cash Flow

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める